ENTA News and Press, Enanta Pharmaceuticals Inc. From 08/08/22

Enanta Pharma press release ( NASDAQ: ENTA ): Q3 GAAP EPS of -$1.53 misses by $0.16 . Revenue of $19.48M (-9.8% Y/Y) misses by $1.25M . For further details see: Enanta Pharma GAAP EPS of -$1.53 misses by $0.16, revenue of $19.48M misses by $1.25M

Presented Positive Phase 1 Study Data for EDP-235, a Coronavirus 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19; Phase 2 Study Planned to Start in 4Q 2022 Progressing Respiratory Syncytial Virus (RSV) Portfolio with a Phase 2 Study of...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Of...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 afte...

Enanta Pharmaceuticals ( NASDAQ: ENTA ) said its potential oral COVID-19 therapy EDP-235 was seen to be safe and tolerable in a phase 1 study. The company added that data from the trial supports advancing EDP-235 into a phase 2 study using once-daily dosing, ...

– 200mg and 400mg Once-Daily Doses Achieved Strong Exposure Multiples Over EC 90 and Were Generally Safe and Well-Tolerated – Plan to Initiate Phase 2 Study in 4Q 2022 Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology ...

Arrowhead Pharmaceuticals ( ARWR ), a clinical-stage biotech focused on RNA interference (RNAi) therapeutics surged on above average volume on Wednesday in solidarity with several other drug developers targeting the liver disease, non-alcoholic steatohepatitis (NASH). Despite ...

Korn/Ferry (NYSE:KFY) represented one of the standout gainers in Wednesday's intraday trading, climbing in the wake of a strong earnings report. Meanwhile, Enanta (ENTA) rose after filing a patent infringement suit related to Pfizer's (PFE) Paxlovid COVID drug. New Relic (NEWR) also made the ...

According to a Lawsuit filed on Tuesday in U.S. District Court for the District of Massachusetts, Pfizer's blockbuster COVID drug Paxlovid violates biotechnology company Enanta Pharmaceuticals's (NASDAQ:ENTA) patent for its COVID drug still in development. The suit is seeking damage...

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, announced today that it has filed suit in United States District Court for the District of Massachusetts ag...